Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing

ABSTRACT

This review focuses on the emerging monoclonal antibody market for infectious diseases and the metric ton scale manufacturing requirements to meet global demand. Increasing access to existing antibody-based products coupled with the unmet need in infectious disease will likely exceed the current existing global manufacturing capacity. Further, the large numbers of individuals infected during epidemics such as the ongoing COVID-19 pandemic emphasizes the need to plan for metric ton manufacturing of monoclonal antibodies by expanding infrastructure and exploring alternative production systems.

KEYWORDS:

• Monoclonal
• passive immunization
• manufacturing
• scale

Acknowledgments

The authors would like to thank Drs. Richard Cone, Peter Lambooy, Jim McDonough, Crystal Moyer, Leigh Pierce, and Erin Grace Sparrow for their helpful comments on the manuscript.

Disclosure of potential conflicts of interest

The authors are developing antibody-based products for the prevention and treatment of infectious diseases.

Additional information

Funding

This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number [U19AI142777, U19AI142764, U19AI142785]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.